AS02A in Malaria‐Naive Adults: Safety, Efficacy, and Immunologic Associates of Protection (original) (raw)

2009, The Journal of Infectious Diseases

See the editorial commentary by Bremen and Plowe, on pages 317-20, and the article by Sacarlal et al, on pages 329-36.) Background. To further increase the eff cacy of malaria vaccine RTS,S/AS02A, we tested the RTS,S antigen formulated using the AS01B Adjuvant System (GlaxoSmithKline Biologicals). Methods. In a double-blind, randomized trial, 102 healthy volunteers were evenly allocated to receive RTS,S/ AS01B or RTS,S/AS02A vaccine at months 0, 1, and 2 of the study, followed by malaria challenge. Protected vaccine recipients were rechallenged 5 months later. Results. RTS,S/AS01B and RTS,S/AS02A were well tolerated and were safe. The efficac of RTS,S/AS01B and RTS,S/AS02A was 50% (95% confidenc interval [CI], 32.9%-67.1%) and 32% (95% CI, 17.6%-47.6%), respectively. At the time of initial challenge, the RTS,S/AS01B group had greater circumsporozoite protein (CSP)-specifi immune responses, including higher immunoglobulin (Ig) G titers, higher numbers of CSP-specifi CD4 + T cells expressing у2 activation markers (interleukin-2, interferon [IFN]-g, tumor necrosis factor-a, or CD40L), and more ex vivo IFN-g enzyme-linked immunospots (ELISPOTs) than did the RTS,S/AS02A group. Protected vaccine recipients had a higher CSP-specifi IgG titer (geometric mean titer, 188 vs 73 mg/mL;